You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
|
---|---|
Published in |
Frontiers in oncology, July 2014
|
DOI | 10.3389/fonc.2014.00171 |
Pubmed ID | |
Authors |
Jolijn W. Groeneweg, Celeste M. DiGloria, Jing Yuan, William S. Richardson, Whitfield B. Growdon, Sriram Sathyanarayanan, Rosemary Foster, Bo R. Rueda |
Abstract |
Ovarian cancer (OvCa) is the most lethal gynecologic malignancy in the United States because of chemoresistant recurrent disease. Our objective was to investigate the efficacy of inhibiting the Notch pathway with a γ-secretase inhibitor (GSI) in an OvCa patient-derived xenograft model as a single agent therapy and in combination with standard chemotherapy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Romania | 1 | 33% |
United States | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Unknown | 23 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 29% |
Researcher | 5 | 21% |
Student > Master | 4 | 17% |
Student > Postgraduate | 2 | 8% |
Professor | 1 | 4% |
Other | 3 | 13% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 33% |
Agricultural and Biological Sciences | 5 | 21% |
Biochemistry, Genetics and Molecular Biology | 4 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
Nursing and Health Professions | 1 | 4% |
Other | 1 | 4% |
Unknown | 2 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2023.
All research outputs
#6,761,242
of 25,394,764 outputs
Outputs from Frontiers in oncology
#2,219
of 22,440 outputs
Outputs of similar age
#59,178
of 240,441 outputs
Outputs of similar age from Frontiers in oncology
#12
of 95 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,441 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.